Summary
The U.S. is cutting funding for mRNA vaccine development, as announced by Health and Human Services Secretary Robert F. Kennedy Jr. The decision affects 22 projects and aligns with President Donald Trump's actions, which have often challenged vaccine development efforts. Some experts argue this could impact the U.S. response to future virus outbreaks.
Key Facts
- The U.S. government, led by Secretary Kennedy, is canceling $500 million worth of projects on mRNA vaccine development.
- The decision impacts institutions like Emory University and companies like Pfizer and Moderna.
- mRNA vaccines help the body create proteins to build immunity but differ from traditional vaccines.
- Kennedy states mRNA vaccines are ineffective against virus mutations based on reviews by BARDA.
- President Trump has previously aimed to reduce funding for vaccine programs.
- Concerns include increased vaccine hesitancy and potential harm to public health, especially for children.
- Experts say no vaccines currently solve the mutation problem, making the funding cuts controversial.
